BNOX
BNOX Real Time Price USDRecent trades of BNOX by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by BNOX's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
Estimated quarterly lobbying spending
BNOX Revenue by Segment or Geography
New patents grants
-
Patent Title: Substituted-n-heteroaryl compounds and uses thereof Nov. 12, 2024
-
Patent Title: Substituted-pyridinyl compounds and uses thereof Sep. 17, 2024
-
Patent Title: Modulators of ion channel receptors and uses thereof Jan. 30, 2024
-
Patent Title: Antibody and checkpoint inhibitor combination therapy May. 23, 2023
-
Patent Title: Method for treating acute myeloid leukemia Oct. 25, 2022
-
Patent Title: Modulators of ion channel receptors and uses thereof Jul. 12, 2022
-
Patent Title: Anxiolytic compounds Mar. 23, 2021
-
Patent Title: Method of treating cancer by administering an anti-lgr5 monoclonal antibody Aug. 18, 2020
-
Patent Title: Predictive biomarkers Feb. 18, 2020
-
Patent Title: Predictive baseline biomarkers for use of vascular disrupting agents Dec. 31, 2019
-
Patent Title: Humanized antibodies that bind lgr5 Jul. 23, 2019
-
Patent Title: Salts, co-crystals, and polymorphs of an anxiolytic compound Apr. 23, 2019
-
Patent Title: Anxiolytic compounds Mar. 19, 2019
-
Patent Title: Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors Feb. 26, 2019
-
Patent Title: Methods of inhibiting growth of a colon cancer tumor in a subject by administering monoclonal antibodies to g protein-coupled receptor 49 (gpr49) Feb. 05, 2019
-
Patent Title: Predicting response to cancer therapy Dec. 25, 2018
-
Patent Title: Combination treatment protocol Nov. 27, 2018
-
Patent Title: Method for treating chronic lymphocytic leukemia Jun. 05, 2018
-
Patent Title: Anxiolytic compounds May. 22, 2018
-
Patent Title: Amine derivatives as potassium channel blockers Mar. 13, 2018
-
Patent Title: Crystalline form of an anxiolytic compound Sep. 12, 2017
-
Patent Title: Salts, co-crystals, and polymorphs of an anxiolytic compound Aug. 29, 2017
-
Patent Title: Antibodies that bind lgr4, their use in inhibiting neoplastic cells and in treating tumors Apr. 25, 2017
-
Patent Title: Anxiolytic compounds Feb. 21, 2017
-
Patent Title: Humanized antibodies that bind lgr5 Jan. 17, 2017
-
Patent Title: Amine derivatives as potassium channel blockers Nov. 15, 2016
-
Patent Title: Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors May. 24, 2016
-
Patent Title: Anti-gpr49 monoclonal antibodies Dec. 29, 2015
-
Patent Title: Methods of inhibiting solid tumor growth by administering gpr49 antibodies Dec. 29, 2015
-
Patent Title: Methods of treating cancer by administering anti-gpr49 antibodies Dec. 29, 2015
-
Patent Title: Methods for preparing naphthyridines Sep. 15, 2015
-
Patent Title: Positive allosteric modulators of the α7 nicotinic acetylcholine receptor and uses thereof Jun. 23, 2015
-
Patent Title: Small-molecules as therapeutics May. 05, 2015
-
Patent Title: Combination therapy for treating proliferative diseases Apr. 14, 2015
-
Patent Title: Anxiolytic compounds Dec. 09, 2014
-
Patent Title: Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors May. 06, 2014
-
Patent Title: Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors Mar. 25, 2014
-
Patent Title: Chemical processes for the manufacture of substituted benzofurans Mar. 18, 2014
-
Patent Title: Anxiolytic compounds Dec. 24, 2013
-
Patent Title: Tubulin polymerisation inhibitors Oct. 15, 2013
-
Patent Title: Anxiolytic compounds Oct. 08, 2013
-
Patent Title: Potassium channel blockers and uses thereof Aug. 13, 2013
-
Patent Title: Furo[2,3-d]pyrimidines and related compounds and methods for treating disease states by inhibiting tubulin polymerization Jun. 18, 2013
-
Patent Title: Benzofuran potassium channel blockers and uses thereof Nov. 13, 2012
-
Patent Title: Methods of identifying agents that inhibit angiogenesis Nov. 13, 2012
-
Patent Title: Anxiolytic compounds Oct. 23, 2012
-
Patent Title: Diagnostic method for epilepsy Oct. 16, 2012
-
Patent Title: Chromenone potassium channel blockers and uses thereof Jul. 10, 2012
-
Patent Title: Aryl potassium channel blockers and uses thereof Jun. 19, 2012
-
Patent Title: Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors Jun. 12, 2012
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to BNOX
Recent picks made for BNOX stock on CNBC
ETFs with the largest estimated holdings in BNOX
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $BNOX stock a Buy, Sell, or Hold?
- What is the price target for $BNOX stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $BNOX stock?
- Who owns the most shares of $BNOX stock?
- What funds own $BNOX stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view BNOX Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.